20:08 , Mar 1, 2019 |  BC Week In Review  |  Company News

Sarepta acquires Myonexus, reports LGMD trial results

Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a pipeline of five gene therapy candidates to treat forms of limb-girdle muscular dystrophy (LGMD). Sarepta also revealed...
15:47 , Feb 27, 2019 |  BC Extra  |  Company News

On strength of first LGMD data, Sarepta exercises option to buy Myonexus

Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a pipeline of five gene therapy candidates to treat forms of limb-girdle muscular dystrophy (LGMD). Sarepta also revealed...
07:00 , Oct 29, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Sarcoglycan γ (SGCG)

Musculoskeletal disease INDICATION: Muscular dystrophy Insect, mouse and patient sample studies suggest exon skipping could help treat limb girdle muscular dystrophy type 2C (LGMD 2C), which is caused by frameshift mutations in exon 6 of...
07:00 , Oct 29, 2015 |  BC Innovations  |  Translation in Brief

Skipping over a rare disease

A team from Northwestern University has expanded the exon-skipping approach used for Duchenne muscular dystrophy (DMD) to a rarer form of muscular dystrophy, limb girdle muscular dystrophy type 2C (LGMD 2C), by targeting the key...